Informatica Expands Seamless AI-Ready Cloud Data Management for Databricks on Google Cloud with New Integration
Informatica ( NYSE: INFA), a leader in enterprise AI-powered cloud data management, today announced the expansion of its Intelligent Data Management Cloud (IDMC) platform services on Google Cloud. The announcements were made at Google Cloud Next 2025. The enhanced capabilities include support for t he Databricks Data Intelligence Platform, API Center and Cloud Data Access Management (CDAM) services running natively on Google Cloud.
'We're pleased to see the deepening relationship between Google and Informatica,' said Ritika Suri, Managing Director, AI & Data ISV Partnerships at Google Cloud. 'These expanded capabilities on Google Cloud will make it easier for our joint customers to ensure their data is AI-ready, enabling more advanced AI use cases like agentic AI in Google Cloud.'
The expanded IDMC services on Google Cloud include the following:
Full Support for Databricks on Google Cloud with 300+ connectors for data ingestion
No-code data pipelines running natively within Databricks for data preparation and transformation
Data quality and profiling for data within the Databricks Data Intelligence platform
Enterprise-wide data governance with seamless integration with Unity Catalog
API Center - next generation API Management to expose data products and data processes as a rich API ecosystem including:
Deployment of APIs across cloud, on-premises or hybrid environments
Ability to expose any IDMC process as an API
Definition of GenAI and Agent APIs for AI apps and processes
Enhanced API security features including rate limiting and IP filtering
API governance for enterprise services, business processes and AI apps
Advanced monitoring to identify and analyze unauthorized access attempts
Cloud Data Access Management - enables organizations to share and use their data while supporting access policy compliance via automated controls:
Intuitive policy authoring aligned with business use, risk tolerance and regulatory frameworks such as EU GDPR, CPRA, or HIPAA without the need to code
Accelerates access to trusted data through simplified request and approval workflows
'Informatica's expanded services with Databricks on Google Cloud delivers a seamless experience that will benefit our joint customers as they build data intelligence,' said Roger Murff, Vice President of Technology Partners at Databricks. 'This unified approach helps eliminate data silos between platforms, enabling organizations to manage their data assets holistically while leveraging the full capabilities of both Databricks and Informatica IDMC on Google Cloud.'
These expanded services offer customers cost efficiency for their data platforms with integration to BigQuery for scale, governance, and model inference, as well as integration with Vertex AI for advanced use cases and agentic workflows.
Rik Tamm-Daniels, Global Vice President at Informatica said, 'This strategic expansion with Google Cloud and Databricks enables our joint customers to accelerate their GenAI, AI and analytics initiatives while maintaining the highest levels of data governance and security. Together, Informatica and Google Cloud enable better business outcomes across a wide variety of industries, including retail, financial services and healthcare. Organizations can leverage the Informatica-Google Cloud partnership to improve their customer experiences, optimize supply chains and enhance compliance with a strong foundation of trusted data.'
For more information, visit Informatica at Google Next, booth #1812.
About Informatica
Informatica (NYSE: INFA), a leader in enterprise AI-powered cloud data management, brings data and AI to life by empowering businesses to realize the transformative power of their most critical assets. We have created a new category of software, the Informatica Intelligent Data Management Cloud™ (IDMC). IDMC is an end-to-end data management platform, powered by CLAIRE® AI, that connects, manages and unifies data across any multi-cloud or hybrid system, democratizing data and enabling enterprises to modernize and advance their business strategies. Customers in approximately 100 countries, including more than 80 of the Fortune 100, rely on Informatica to drive data-led digital transformation. Informatica. Where data and AI come to life.
SOURCE: Informatica
Copyright Business Wire 2025.
PUB: 04/09/2025 08:30 AM/DISC: 04/09/2025 08:32 AM
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a minute ago
- Yahoo
Is There Now An Opportunity In TransDigm Group Incorporated (NYSE:TDG)?
Today we're going to take a look at the well-established TransDigm Group Incorporated (NYSE:TDG). The company's stock received a lot of attention from a substantial price movement on the NYSE over the last few months, increasing to US$1,621 at one point, and dropping to the lows of US$1,373. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether TransDigm Group's current trading price of US$1,388 reflective of the actual value of the large-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let's take a look at TransDigm Group's outlook and value based on the most recent financial data to see if there are any catalysts for a price change. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. Is TransDigm Group Still Cheap? According to our valuation model, TransDigm Group seems to be fairly priced at around 0.57% above our intrinsic value, which means if you buy TransDigm Group today, you'd be paying a relatively fair price for it. And if you believe the company's true value is $1380.06, then there isn't really any room for the share price grow beyond what it's currently trading. Although, there may be an opportunity to buy in the future. This is because TransDigm Group's beta (a measure of share price volatility) is high, meaning its price movements will be exaggerated relative to the rest of the market. If the market is bearish, the company's shares will likely fall by more than the rest of the market, providing a prime buying opportunity. See our latest analysis for TransDigm Group What kind of growth will TransDigm Group generate? Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. TransDigm Group's earnings over the next few years are expected to increase by 47%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value. What This Means For You Are you a shareholder? It seems like the market has already priced in TDG's positive outlook, with shares trading around its fair value. However, there are also other important factors which we haven't considered today, such as the track record of its management team. Have these factors changed since the last time you looked at the stock? Will you have enough conviction to buy should the price fluctuates below the true value? Are you a potential investor? If you've been keeping an eye on TDG, now may not be the most advantageous time to buy, given it is trading around its fair value. However, the optimistic prospect is encouraging for the company, which means it's worth diving deeper into other factors such as the strength of its balance sheet, in order to take advantage of the next price drop. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. Be aware that TransDigm Group is showing 3 warning signs in our investment analysis and 2 of those can't be ignored... If you are no longer interested in TransDigm Group, you can use our free platform to see our list of over 50 other stocks with a high growth potential. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Yahoo
a minute ago
- Yahoo
The three-year loss for CVS Health (NYSE:CVS) shareholders likely driven by its shrinking earnings
CVS Health Corporation (NYSE:CVS) shareholders should be happy to see the share price up 11% in the last month. But that doesn't change the fact that the returns over the last three years have been less than pleasing. After all, the share price is down 34% in the last three years, significantly under-performing the market. Although the past week has been more reassuring for shareholders, they're still in the red over the last three years, so let's see if the underlying business has been responsible for the decline. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One imperfect but simple way to consider how the market perception of a company has shifted is to compare the change in the earnings per share (EPS) with the share price movement. CVS Health saw its EPS decline at a compound rate of 17% per year, over the last three years. This fall in the EPS is worse than the 13% compound annual share price fall. So, despite the prior disappointment, shareholders must have some confidence the situation will improve, longer term. The graphic below depicts how EPS has changed over time (unveil the exact values by clicking on the image). It's good to see that there was some significant insider buying in the last three months. That's a positive. That said, we think earnings and revenue growth trends are even more important factors to consider. It might be well worthwhile taking a look at our free report on CVS Health's earnings, revenue and cash flow. What About Dividends? When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR is a return calculation that accounts for the value of cash dividends (assuming that any dividend received was reinvested) and the calculated value of any discounted capital raisings and spin-offs. It's fair to say that the TSR gives a more complete picture for stocks that pay a dividend. We note that for CVS Health the TSR over the last 3 years was -26%, which is better than the share price return mentioned above. This is largely a result of its dividend payments! A Different Perspective It's good to see that CVS Health has rewarded shareholders with a total shareholder return of 23% in the last twelve months. And that does include the dividend. Since the one-year TSR is better than the five-year TSR (the latter coming in at 5% per year), it would seem that the stock's performance has improved in recent times. In the best case scenario, this may hint at some real business momentum, implying that now could be a great time to delve deeper. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. To that end, you should learn about the 3 warning signs we've spotted with CVS Health (including 1 which is a bit unpleasant) . If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: most of them are flying under the radar). Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
a minute ago
- Yahoo
Elevance Health (NYSE:ELV) Is Reinvesting At Lower Rates Of Return
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Amongst other things, we'll want to see two things; firstly, a growing return on capital employed (ROCE) and secondly, an expansion in the company's amount of capital employed. If you see this, it typically means it's a company with a great business model and plenty of profitable reinvestment opportunities. Having said that, from a first glance at Elevance Health (NYSE:ELV) we aren't jumping out of our chairs at how returns are trending, but let's have a deeper look. Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. What Is Return On Capital Employed (ROCE)? For those who don't know, ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business. To calculate this metric for Elevance Health, this is the formula: Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities) 0.11 = US$8.7b ÷ (US$122b - US$44b) (Based on the trailing twelve months to June 2025). So, Elevance Health has an ROCE of 11%. By itself that's a normal return on capital and it's in line with the industry's average returns of 11%. See our latest analysis for Elevance Health In the above chart we have measured Elevance Health's prior ROCE against its prior performance, but the future is arguably more important. If you'd like, you can check out the forecasts from the analysts covering Elevance Health for free. What Does the ROCE Trend For Elevance Health Tell Us? In terms of Elevance Health's historical ROCE movements, the trend isn't fantastic. Around five years ago the returns on capital were 14%, but since then they've fallen to 11%. Although, given both revenue and the amount of assets employed in the business have increased, it could suggest the company is investing in growth, and the extra capital has led to a short-term reduction in ROCE. And if the increased capital generates additional returns, the business, and thus shareholders, will benefit in the long run. The Bottom Line While returns have fallen for Elevance Health in recent times, we're encouraged to see that sales are growing and that the business is reinvesting in its operations. These trends are starting to be recognized by investors since the stock has delivered a 16% gain to shareholders who've held over the last five years. Therefore we'd recommend looking further into this stock to confirm if it has the makings of a good investment. Elevance Health could be trading at an attractive price in other respects, so you might find our on our platform quite valuable. For those who like to invest in solid companies, check out this free list of companies with solid balance sheets and high returns on equity. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
